Hengrui Pharma stock gains 20% by end of 2026

Hengrui Pharma's stock will likely gain 20% by the end of 2026 as investors react to the $15B licensing deal and its long-term revenue potential. The deal validates Hengrui's R&D and commercial strategy, attracting institutional investors.

Implied probability (Yes)

65%